American Psychological Association. DSM-5: diagnostic and statistical manual of mental disorders. Washington: American Psychiatricl Publishing; 2013.
Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602.
Leray E, Camara A, Drapier D, Riou F, Bougeant N, Pelissolo A, et al. Prevalence, characteristics and comorbidities of anxiety disorders in France: results from the “Mental Health in General Population” survey (MHGP). Eur Psychiatry J Assoc Eur Psychiatr. 2011;26:339–45.
Bruce SE, Yonkers KA, Otto MW, Eisen JL, Weisberg RB, Pagano M, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry. 2005;162:1179–87.
Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012;16:77–84.
Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015;30:183–92.
Perna G, Alciati A, Riva A, Micieli W, Caldirola D. Long-term pharmacological treatments of anxiety disorders: an updated systematic review. Curr Psychiatry Rep. 2016;18:23.
Weber SR, Wehr AM, Duchemin A-M. Prevalence of antipsychotic prescriptions among patients with anxiety disorders treated in inpatient and outpatient psychiatric settings. J Affect Disord. 2016;191:292–9.
Delay J, Deniker P, Hari J. Utilisation en thérapeutique psychiatrique d’une phénothiazine d’action centrale sélective (4560 PR). Ann Med Psychol. 1952:112–7.
Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379:2063–71.
Miura T, Noma H, Furukawa TA, Mitsuyasu H, Tanaka S, Stockton S, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1:351–9.
Young S, Pfaff D, Lewandowski KE, Ravichandran C, Cohen BM, Öngür D. Anxiety disorder comorbidity in bipolar disorder. Schizophr Schizoaffective Disord Psychopathol. 2013;46:176–85.
Saha S, Scott J, Varghese D, McGrath J. Anxiety and depressive disorders are associated with delusional-like experiences: a replication study based on a National Survey of Mental Health and Wellbeing. BMJ Open. 2012;2
Pignon B, Schürhoff F, Szöke A, Geoffroy PA, Jardri R, Roelandt J-L, et al. Sociodemographic and clinical correlates of psychotic symptoms in the general population: findings from the MHGP survey. Schizophr. Res. 2017. Available from: http://www.sciencedirect.com/science/article/pii/S0920996417303924
Garay RP, Samalin L, Hameg A, Llorca P-M. Investigational drugs for anxiety in patients with schizophrenia. Expert Opin Investig Drugs. 2015;24:507–17.
Marques TR, Levine SZ, Reichenberg A, Kahn R, Derks EM, Fleischhacker WW, et al. How antipsychotics impact the different dimensions of schizophrenia: a test of competing hypotheses. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2014;24:1279–88.
Gao K, Muzina D, Gajwani P, Calabrese JR. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry. 2006;67:1327–40.
Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull. 2012;38:167–77.
van Os J, Fahy T, Jones P, Harvey I, Toone B, Murray R. Tardive dyskinesia: who is at risk? Acta Psychiatr Scand. 1997;96:206–16.
Hershenberg R, Gros DF, Brawman-Mintzer O. Role of atypical antipsychotics in the treatment of generalized anxiety disorder. CNS Drugs. 2014;28:519–33.
Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.
Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM, et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66(Suppl 5):40–8.
Roberts RJ, Lohano KK, El-Mallakh RS. Antipsychotics as antidepressants. Asia-Pac Psychiatry Off J Pac Rim Coll Psychiatr. 2016;8:179–88.
Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. 4 edition. Cambridge: Cambridge University Press; 2013.
Carton L, Cottencin O, Lapeyre-Mestre M, Geoffroy PA, Favre J, Simon N, et al. Off-label prescribing of antipsychotics in adults, children and elderly individuals: a systematic review of recent prescription trends. Curr Pharm Des. 2015;21:3280–97.
Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166:1021–6.
Keltner NL. Biological perspectives. Metabolic syndrome: schizophrenia and atypical antipsychotics. Perspect Psychiatr Care. 2006;42:204.
Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet Lond Engl. 2006;368:2156–66.
Weisberg RB. Overview of generalized anxiety disorder: epidemiology, presentation, and course. J Clin Psychiatry. 2009;70(Suppl 2):4–9.
Grant BF, Hasin DS, Stinson FS, Dawson DA, June Ruan W, Goldstein RB, et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2005;35:1747–59.
Kessler RC, Gruber M, Hettema JM, Hwang I, Sampson N, Yonkers KA. Co-morbid major depression and generalized anxiety disorders in the National Comorbidity Survey follow-up. Psychol Med. 2008;38:365–74.
Yonkers KA, Bruce SE, Dyck IR, Keller MB. Chronicity, relapse, and illness—course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up. Depress Anxiety. 2003;17:173–9.
Bereza BG, Machado M, Einarson TR. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder. Clin Ther. 2009;31:1279–308.
Hoffman DL, Dukes EM, Wittchen H-U. Human and economic burden of generalized anxiety disorder. Depress Anxiety. 2008;25:72–90.
National Institute for Health and Clinical Excellence (NICE). Generalised anxiety disorder overview—NICE Pathways [Internet]. 2012 [cited 2017 Jan 25]. Available from: https://pathways.nice.org.uk/pathways/generalised-anxiety-disorder
Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14:S1.
Bagby RM, Quilty LC. Review: cognitive behavioural therapy is more effective than control and similarly effective to pharmacotherapy for generalised anxiety disorder. Evid Based Ment Health. 2006;9:43.
Hunot V, Churchill R, Silva de Lima M, Teixeira V. Psychological therapies for generalised anxiety disorder. Cochrane Database Syst. Rev. 2007;CD001848.
Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2003;160:749–56.
Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology. 2005;177:280–8.
Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2005;66:1321–5.
Pandina GJ, Canuso CM, Turkoz I, Kujawa M, Mahmoud RA. Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial. Psychopharmacol Bull. 2007;40:41–57.
Patterson B, Van Ameringen M. Augmentation strategies for treatment-resistant anxiety disorders: a systematic review and meta-analysis. Depress Anxiety. 2016;33:728–36.
Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006;59:211–5.
Menza MA, Dobkin RD, Marin H. An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder. J Clin Psychopharmacol. 2007;27:207–10.
Hoge EA, Worthington JJ, Kaufman RE, Delong HR, Pollack MH, Simon NM. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr. 2008;13:522–7.
• Lohoff FW, Etemad B, Mandos LA, Gallop R, Rickels K. Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study. J Clin Psychopharmacol. 2010;30:185–9. This RCT of ziprasidone in monotherapy or adjunctive treatment vs. placebo in refractory GAD patients did not show any significant difference in reduction of anxiety symptoms.
Simon NM, Connor KM, LeBeau RT, Hoge EA, Worthington JJ, Zhang W, et al. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology. 2008;197:675–81.
• Altamura AC, Serati M, Buoli M, Dell’Osso B. Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study. Int Clin Psychopharmacol. 2011;26:201–5. This placebo-controlled RCT of quetiapine augmentation in refractory GAD patients showed a higher rate of responders among the quetiapine group than placebo.
Maher AR, Theodore G. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J Manag Care Pharm JMCP. 2012;18:S1–20.
Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol. 2010;13:305–20.
Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2011;31:418–28.
Merideth C, Cutler AJ, She F, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol. 2012;27:40–54.
•• Maneeton N, Maneeton B, Woottiluk P, Likhitsathian S, Suttajit S, Boonyanaruthee V, et al. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2016;10:259–76. This meta-analysis of RCT of quetiapine in non-refractory GAD showed a significant effect (reduction of anxiety symptoms and increase of responders’ rate).
• Sheehan DV, Svedsäter H, Locklear JC, Eriksson H. Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study. J Affect Disord. 2013;151:906–13. This open-label study showed that sulpiride monotherapy in refractory-PD led to significant clinical improvement. This placebo-controlled RCT showed an efficacy of quetiapine monotherapy in GAD patients which showed long-term efficacy of quetiapine on functioning and sleep quality.
Endicott J, Svedsäter H, Locklear JC. Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder. Neuropsychiatr Dis Treat. 2012;8:301–11.
Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2011;26:11–24.
Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol Oxf Engl. 2014;28:403–39.
Bandelow B, Zohar J, Kasper S, Möller H-J. How to grade categories of evidence. World J Biol Psychiatry. 2008;9:242–7.
Heimberg RG, Hofmann SG, Liebowitz MR, Schneier FR, Smits JAJ, Stein MB, et al. Social anxiety disorder in DSM-5. Depress Anxiety. 2014;31:472–9.
Peyre H, Hoertel N, Rivollier F, Landman B, McMahon K, Chevance A, et al. Latent class analysis of the feared situations of social anxiety disorder: a population-based study. Depress Anxiety. 2016;33:1178–87.
Katzelnick DJ, Kobak KA, DeLeire T, Henk HJ, Greist JH, Davidson JR, et al. Impact of generalized social anxiety disorder in managed care. Am J Psychiatry. 2001;158:1999–2007.
Kushnir J, Marom S, Mazar M, Sadeh A, Hermesh H. The link between social anxiety disorder, treatment outcome, and sleep difficulties among patients receiving cognitive behavioral group therapy. Sleep Med. 2014;15:515–21.
Schneier FR, Foose TE, Hasin DS, Heimberg RG, Liu S-M, Grant BF, et al. Social anxiety disorder and alcohol use disorder co-morbidity in the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2010;40:977–88.
Davis ML, Smits JAJ, Hofmann SG. Update on the efficacy of pharmacotherapy for social anxiety disorder: a meta-analysis. Expert Opin Pharmacother. 2014;15:2281–91.
Fehm L, Pelissolo A, Furmark T, Wittchen H-U. Size and burden of social phobia in Europe. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2005;15:453–62.
Ruscio AM, Brown TA, Chiu WT, Sareen J, Stein MB, Kessler RC. Social fears and social phobia in the USA: results from the National Comorbidity Survey Replication. Psychol Med. 2008;38:15–28.
Grant BF, Hasin DS, Blanco C, Stinson FS, Chou SP, Goldstein RB, et al. The epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2005;66:1351–61.
National Institute for Health and Clinical Excellence (NICE). Social anxiety disorder: recognition, assessment and treatment. Clinical guideline [Internet]. 2013 [cited 2017 Apr 10]. Available from: https://www.nice.org.uk/guidance/cg159?unlid=107165807620164922324
Yoshinaga N, Niitsu T, Hanaoka H, Sato Y, Ohshima F, Matsuki S, et al. Strategy for treating selective serotonin reuptake inhibitor-resistant social anxiety disorder in the clinical setting: a randomised controlled trial protocol of cognitive behavioural therapy in combination with conventional treatment. BMJ Open. 2013;3
Stein MB, Stein DJ. Social anxiety disorder. Lancet Lond Engl. 2008;371:1115–25.
Blanco C, Bragdon LB, Schneier FR, Liebowitz MR. The evidence-based pharmacotherapy of social anxiety disorder. Int J Neuropsychopharmacol. 2013;16:235–49.
Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JRT. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol Oxf Engl. 2002;16:365–8.
Simon NM, Hoge EA, Fischmann D, Worthington JJ, Christian KM, Kinrys G, et al. An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006;67:381–5.
Vaishnavi S, Alamy S, Zhang W, Connor KM, Davidson JRT. Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31:1464–9.
Schutters SIJ, van Megen HJGM, Westenberg HGM. Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study. J Clin Psychiatry. 2005;66:540–2.
Komossa K1, Depping AM, Gaudchau A, Kissling W, Leucht S. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst. Rev. 2010;12:CD008121. doi:10.1002/14651858.CD008121.pub2.
Donahue CB, Kushner MG, Thuras PD, Murphy TG, Van Demark JB, Adson DE. Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia. J Anxiety Disord. 2009;23:362–8.
Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006;63:415–24.
Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H-U. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21:169–84.
Bystritsky A, Kerwin L, Niv N, Natoli JL, Abrahami N, Klap R, et al. Clinical and subthreshold panic disorder. Depress Anxiety. 2010;27:381–9.
National Institute for Health and Clinical Excellence (NICE). Generalised anxiety disorder and panic disorder in adults: management. Guidance and guidelines NICE [Internet]. 2011 [cited 2017 Apr 16]. Available from: https://www.nice.org.uk/guidance/cg113?unlid=50950734120166612729
Freire RC, Machado S, Arias-Carrión O, Nardi AE. Current pharmacological interventions in panic disorder. CNS Neurol Disord Drug Targets. 2014;13:1057–65.
Batelaan NM, de Graaf R, Penninx BW, van Balkom AJ, Vollebergh WA, Beekman AT. The 2-year prognosis of panic episodes in the general population. Psychol Med. 2010;40:147–57.
Freire RC, Zugliani MM, Garcia RF, Nardi AE. Treatment-resistant panic disorder: a systematic review. Expert Opin Pharmacother. 2016;17:159–68.
Prosser JM, Yard S, Steele A, Cohen LJ, Galynker II. A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study. BMC Psychiatry. 2009;9:25.
Wang HR, Woo YS, Bahk W-M. The potential role of atypical antipsychotics in the treatment of panic disorder. Hum Psychopharmacol. 2014;29:405–13.
Hollifield M, Thompson PM, Ruiz JE, Uhlenhuth EH. Potential effectiveness and safety of olanzapine in refractory panic disorder. Depress Anxiety. 2005;21:33–40.
Sepede G, De Berardis D, Gambi F, Campanella D, La Rovere R, D’Amico M, et al. Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol. 2006;26:45–9.
• Nunes EA, Freire RC, Dos Reis M, de OliveiraESilva AC, Machado S, JAS C, et al. Sulpiride and refractory panic disorder. Psychopharmacology. 2012;223:247–9. This open-label study showed that sulpiride monotherapy in refractory-PD led to significant clinical improvement.
• Goddard AW, Mahmud W, Medlock C, Shin Y-W, Shekhar A. A controlled trial of quetiapine XR coadministration treatment of SSRI-resistant panic disorder. Ann General Psychiatry. 2015;14:26. In this RCT, among 26 patients with SSRI-resistant panic disorder, quetiapine augmentation was not associated with a significant clinical difference.
Gao K, Wu R, Kemp DE, Chen J, Karberg E, Conroy C, et al. Efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: a randomized, placebo-controlled trial. J Clin Psychiatry. 2014;75:1062–8.
National Institute for Health and Clinical Excellence (NICE). Panic disorder overview—NICE Pathways [Internet]. [cited 2017 Aug 1]. Available from: https://pathways.nice.org.uk/pathways/panic-disorder
Giampaolo P, Alessandra A, Raffaele B, Elisa M, Giuseppina D, Paolo C, et al. Is there room for second-generation antipsychotics in the pharmacotherapy of panic disorder? A systematic review based on PRISMA guidelines. Int J Mol Sci. 2016;17:551.
Macy AS, Theo JN, Kaufmann SCV, Ghazzaoui RB, Pawlowski PA, Fakhry HI, et al. Quality of life in obsessive compulsive disorder. CNS Spectr. 2013;18:21–33.
Fontenelle LF, Mendlowicz MV, Versiani M. The descriptive epidemiology of obsessive-compulsive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2006;30:327–37.
Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol. 2002;22:309–17.
Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2005;8:107–29.
Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry. 1989;46:1012–6.
Mallet L, Polosan M, Jaafari N, Baup N, Welter M-L, Fontaine D, et al. Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med. 2008;359:2121–34.
Sugarman MA, Kirsch I, Huppert JD. Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: a meta-analysis. J Affect Disord. 2017;218:217–26.
McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994;51:302–8.
Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry. 2005;66:736–43.
Jiménez-Jiménez FJ, García-Ruiz PJ. Pharmacological options for the treatment of Tourette’s disorder. Drugs. 2001;61:2207–20.
•• Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int. J. Neuropsychopharmacol. 2015;18. This meta-analysis of 14 RCTs concerning 6 different antipsychotics add-on in refractory OCD patients showed significant efficacy of haloperidol, risperidone, and aripiprazole, compared to placebo. Haloperidol induced severe motor side effects. Quetiapine, olanzapine, and paliperidone did not show efficacy.
DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26:649–66.
• Sayyah M, Sayyah M, Boostani H, Ghaffari SM, Hoseini A. Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). Depress Anxiety. 2012;29:850–4. This double-bind placebo-controlled RCT of aripiprazole in refractory
showed an efficacy of aripiprazole in symptom reduction.
• Selvi Y, Atli A, Aydin A, Besiroglu L, Ozdemir P, Ozdemir O. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. Hum Psychopharmacol. 2011;26:51–7. This double-bind placebo-controlled RCT of aripiprazole in refractory OCD showed an efficacy of aripiprazole in symptom reduction.
American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. [Internet]. 2007 [cited 2017 May 9]. Available from: http://www.psych.org/psych_pract/treatg/pg/prac_guide.cfm
Fonseka TM, Richter MA, Müller DJ. Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature. Curr Psychiatry Rep. 2014;16:510.
Bourin M, Dailly E, Hascöet M. Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome. CNS Drug Rev. 2004;10:219–29.
Fourrier A, Gasquet I, Allicar MP, Bouhassira M, Lépine JP, Bégaud B. Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. Br J Clin Pharmacol. 2000;49:80–6.
Diemer J, Domschke K, Mühlberger A, Winter B, Zavorotnyy M, Notzon S, et al. Acute anxiolytic effects of quetiapine during virtual reality exposure—a double-blind placebo-controlled trial in patients with specific phobia. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2013;23:1551–60.
O’brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry. 2005;66(Suppl 2):28–33.
Ames D, Carr-Lopez SM, Gutierrez MA, Pierre JM, Rosen JA, Shakib S, et al. Detecting and managing adverse effects of antipsychotic medications: current state of play. Psychiatr Clin North Am. 2016;39:275–311.
De Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Möller H-J. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry J Assoc Eur Psychiatr. 2009;24:412–24.
De Hert M, Detraux J, Peuskens J. Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review. Expert Opin Drug Saf. 2014;13:605–24.
Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161:1334–49.
Rakofsky JJ, Dunlop BW. Treating nonspecific anxiety and anxiety disorders in patients with bipolar disorder: a review. J Clin Psychiatry. 2011;72:81–90.
Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079–87.
Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs. 2009;23:649–59.
Grant BF, Chou SP, Goldstein RB, Huang B, Stinson FS, Saha TD, et al. Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2008;69:533–45.
Leichsenring F, Leibing E, Kruse J, New AS, Leweke F. Borderline personality disorder. Lancet Lond Engl. 2011;377:74–84.
Keuroghlian AS, Gunderson JG, Pagano ME, Markowitz JC, Ansell EB, Shea MT, et al. Interactions of borderline personality disorder and anxiety disorders over 10 years. J Clin Psychiatry. 2015;76:1529–34.
Nickel MK, Muehlbacher M, Nickel C, Kettler C, Pedrosa Gil F, Bachler E, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006;163:833–8.
Black DW, Zanarini MC, Romine A, Shaw M, Allen J, Schulz SC. Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2014;171:1174–82.
American Psychiatric Association Practice Guidelines. Practice guideline for the treatment of patients with borderline personality disorder. 2010 [cited 2017 Aug 15]; Available from: http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bpd.pdf
National Health and Medical Research Council. Clinical practice guideline for the management of borderline personality disorder [Internet]. 2012 [cited 2017 Aug 21]. Available from: https://www.nhmrc.gov.au/guidelines-publications/mh25